Acute Intermittent Porphyria Market Size, Share, Growth & Industry Analysis, By Treatment (Gonadotropin-Releasing Hormone Analogues, and Prophylactic Hematin Infusions), By End-Users (Hospitals & Clinics, Ambulatory Surgical Centers, and Research Centers), and Regional Analysis, 2024-2031

TABLE OF CONTENT

1 INTRODUCTION OF THE GLOBAL ACUTE INTERMITTENT PORPHYRIA MARKET 
1.1 Market Definition
1.2 Market Segmentation
1.3 Research Timelines
1.4 Limitations
1.5 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY
3.1 Data Collection
3.1.1 Secondary Sources
3.1.2 Primary Sources
3.1.3 Research Flow
3.2 Subject Matter Expert Advice
3.3 Quality Check
3.4 Final Review
3.5 Bottom-Up Approach
3.6 Top-down Approach

4 GLOBAL ACUTE INTERMITTENT PORPHYRIA MARKET OUTLOOK
4.1 Market Evolution
4.2 Overview
4.3 Market Dynamics
4.3.1 Drivers
4.3.2 Restraints
4.3.3 Opportunities
4.3.4 Challenges
4.4 Pricing Analysis
4.5 Porter’s Five Forces Analysis
4.6 Value Chain Analysis
4.7 Macroeconomic Analysis

5 IMPACT OF RUSSIA-UKRAINE WAR

6 GLOBAL ACUTE INTERMITTENT PORPHYRIA MARKET, BY TREATMENT
6.1 Overview
6.2 Gonadotropin-Releasing Hormone Analogues
6.3 Prophylactic Hematin Infusions 

7 GLOBAL ACUTE INTERMITTENT PORPHYRIA MARKET, BY END-USERS
7.1 Overview
7.2 Hospitals & Clinics
7.3  Ambulatory Surgical Centers
7.4 Research Centers

8 GLOBAL ACUTE INTERMITTENT PORPHYRIA MARKET, BY GEOGRAPHY
8.1 Overview

9 NORTH AMERICA 
9.1 U.S.
9.2 Canada
9.3 Mexico

10 EUROPE 
10.1 Germany
10.2 U.K.
10.3 France
10.4 Italy
10.5 Spain
10.6 Russia
10.7 Rest of Europe

11 ASIA-PACIFIC 
11.1 China
11.2 Japan
11.3 India
11.4 South Korea
11.5 Rest of Asia-Pacific

12 MIDDLE EAST & AFRICA 
12.1 GCC
12.2 South Africa
12.3 North Africa
12.4 Rest of Middle East & Africa

13 LATIN AMERICA 
13.1 Brazil
13.2 Argentina
13.3 Rest of South America

14 GLOBAL ACUTE INTERMITTENT PORPHYRIA MARKET COMPETITIVE LANDSCAPE
14.1 Overview
14.2 Key Developments
14.3 Key Strategic Developments
14.4 Company Market Ranking
14.5 Regional Footprint
14.6 Type Footprint

15 COMPANY PROFILES
15.1 Alnylam Pharmaceuticals, Inc. 
15.1.1 Key Facts
15.1.2 Financial Overview
15.1.3 Product Benchmarking
15.1.4 Recent Developments
15.1.5 Winning Imperatives
15.1.6 Current Focus & Strategies
15.1.7 Threat from competition
15.1.8 SWOT Analysis
15.2 Recordati Rare Diseases
15.2.1 Key Facts
15.2.2 Financial Overview
15.2.3 Product Benchmarking
15.2.4 Recent Developments
15.2.5 Winning Imperatives
15.2.6 Current Focus & Strategies
15.2.7 Threat from competition
15.2.8 SWOT Analysis
15.3 Octapharma AG
15.3.1 Key Facts
15.3.2 Financial Overview
15.3.3 Product Benchmarking
15.3.4 Recent Developments
15.3.5 Winning Imperatives
15.3.6 Current Focus & Strategies
15.3.7 Threat from competition
15.3.8 SWOT Analysis
15.4 Clinuvel Pharmaceuticals 
15.4.1 Key Facts
15.4.2 Financial Overview
15.4.3 Product Benchmarking
15.4.4 Recent Developments
15.4.5 Winning Imperatives
15.4.6 Current Focus & Strategies
15.4.7 Threat from competition
15.4.8 SWOT Analysis
15.5 Shandong octagon chemicals limited
15.5.1 Key Facts
15.5.2 Financial Overview
15.5.3 Product Benchmarking
15.5.4 Recent Developments
15.5.5 Winning Imperatives
15.5.6 Current Focus & Strategies
15.5.7 Threat from competition
15.5.8 SWOT Analysis
15.6 Glenmark Pharmaceuticals Ltd
15.6.1 Key Facts
15.6.2 Financial Overview
15.6.3 Product Benchmarking
15.6.4 Recent Developments
15.6.5 Winning Imperatives
15.6.6 Current Focus & Strategies
15.6.7 Threat from competition
15.6.8 SWOT Analysis
15.7 Intas Pharmaceutical Ltd.
15.7.1 Key Facts
15.7.2 Financial Overview
15.7.3 Product Benchmarking
15.7.4 Recent Developments
15.7.5 Winning Imperatives
15.7.6 Current Focus & Strategies
15.7.7 Threat from competition
15.7.8 SWOT Analysis
15.8 Sanofi 
15.8.1 Key Facts
15.8.2 Financial Overview
15.8.3 Product Benchmarking
15.8.4 Recent Developments
15.8.5 Winning Imperatives
15.8.6 Current Focus & Strategies
15.8.7 Threat from competition
15.8.8 SWOT Analysis
15.9 Sun Pharmaceuticals Industries Ltd.
15.9.1 Key Facts
15.9.2 Financial Overview
15.9.3 Product Benchmarking
15.9.4 Recent Developments
15.9.5 Winning Imperatives
15.9.6 Current Focus & Strategies
15.9.7 Threat from competition
15.9.8 SWOT Analysis
15.10 Abbott Healthcare Pvt. Ltd. 
15.10.1 Key Facts
15.10.2 Financial Overview
15.10.3 Product Benchmarking
15.10.4 Recent Developments
15.10.5 Winning Imperatives
15.10.6 Current Focus & Strategies
15.10.7 Threat from competition
15.10.8 SWOT Analysis

List of Tables

TABLE 1 Global Acute Intermittent Porphyria Market Revenue, By Treatment, 2021 – 2031 (USD Million)
TABLE 2 Global Acute Intermittent Porphyria Market Revenue, By End-users, 2021 – 2031 (USD Million)
TABLE 3 Global Acute Intermittent Porphyria Market Revenue, By Geography, 2021 – 2031 (USD Million)
TABLE 4 North America Acute Intermittent Porphyria Market Revenue, By Country, 2021 – 2031 (USD Million)
TABLE 5 North America Acute Intermittent Porphyria Market Revenue, By Treatment, 2021 – 2031 (USD Million)
TABLE 6 North America Acute Intermittent Porphyria Market Revenue, By End-users, 2021 – 2031 (USD Million)
TABLE 7 US Acute Intermittent Porphyria Market Revenue, By Treatment, 2021 – 2031 (USD Million)
TABLE 8 US Acute Intermittent Porphyria Market Revenue, By End-users, 2021 – 2031 (USD Million)
TABLE 9 Canada Acute Intermittent Porphyria Market Revenue, By Treatment, 2021 – 2031 (USD Million)
TABLE 10 Canada Acute Intermittent Porphyria Market Revenue, By End-users, 2021 – 2031 (USD Million)
TABLE 11 Mexico Acute Intermittent Porphyria Market Revenue, By Treatment, 2021 – 2031 (USD Million)
TABLE 12 Mexico Acute Intermittent Porphyria Market Revenue, By End-users, 2021 – 2031 (USD Million)
TABLE 13 Europe Acute Intermittent Porphyria Market Revenue, By Country, 2021 – 2031 (USD Million)
TABLE 14 Europe Acute Intermittent Porphyria Market Revenue, By Treatment, 2021 – 2031 (USD Million)
TABLE 15 Europe Acute Intermittent Porphyria Market Revenue, By End-users, 2021 – 2031 (USD Million)
TABLE 16 Germany Acute Intermittent Porphyria Market Revenue, By Treatment, 2021 – 2031 (USD Million)
TABLE 17 Germany Acute Intermittent Porphyria Market Revenue, By End-users, 2021 – 2031 (USD Million)
TABLE 18 France Acute Intermittent Porphyria Market Revenue, By Treatment, 2021 – 2031 (USD Million)
TABLE 19 France Acute Intermittent Porphyria Market Revenue, By End-users, 2021 – 2031 (USD Million)
TABLE 20 U.K. Acute Intermittent Porphyria Market Revenue, By Treatment, 2021 – 2031 (USD Million)
TABLE 21 U.K. Acute Intermittent Porphyria Market Revenue, By End-users, 2021 – 2031 (USD Million)
TABLE 22 Spain Acute Intermittent Porphyria Market Revenue, By Treatment, 2021 – 2031 (USD Million)
TABLE 23 Spain Acute Intermittent Porphyria Market Revenue, By End-users, 2021 – 2031 (USD Million)
TABLE 24 Italy Acute Intermittent Porphyria Market Revenue, By Treatment, 2021 – 2031 (USD Million)
TABLE 25 Italy Acute Intermittent Porphyria Market Revenue, By End-users, 2021 – 2031 (USD Million)
TABLE 26 Russia Acute Intermittent Porphyria Market Revenue, By Treatment, 2021 – 2031 (USD Million)
TABLE 27 Russia Acute Intermittent Porphyria Market Revenue, By End-users, 2021 – 2031 (USD Million)
TABLE 28 Rest of Europe Acute Intermittent Porphyria Market Revenue, By Treatment, 2021 – 2031 (USD Million)
TABLE 29 Rest of Europe Acute Intermittent Porphyria Market Revenue, By End-users, 2021 – 2031 (USD Million)
TABLE 30 Asia-Pacific Acute Intermittent Porphyria Market Revenue, By Country, 2021 – 2031 (USD Million)
TABLE 31 Asia-Pacific Acute Intermittent Porphyria Market Revenue, By Treatment, 2021 – 2031 (USD Million)
TABLE 32 Asia-Pacific Acute Intermittent Porphyria Market Revenue, By End-users, 2021 – 2031 (USD Million)
TABLE 33 China Acute Intermittent Porphyria Market Revenue, By Treatment, 2021 – 2031 (USD Million)
TABLE 34 China Acute Intermittent Porphyria Market Revenue, By End-users, 2021 – 2031 (USD Million)
TABLE 35 Japan Acute Intermittent Porphyria Market Revenue, By Treatment, 2021 – 2031 (USD Million)
TABLE 36 Japan Acute Intermittent Porphyria Market Revenue, By End-users, 2021 – 2031 (USD Million)
TABLE 37 India Acute Intermittent Porphyria Market Revenue, By Treatment, 2021 – 2031 (USD Million)
TABLE 38 India Acute Intermittent Porphyria Market Revenue, By End-users, 2021 – 2031 (USD Million)
TABLE 39 South Korea Acute Intermittent Porphyria Market Revenue, By Treatment, 2021 – 2031 (USD Million)
TABLE 40 South Korea Acute Intermittent Porphyria Market Revenue, By End-users, 2021 – 2031 (USD Million)
TABLE 41 Rest of Asia-Pacific Acute Intermittent Porphyria Market Revenue, By Treatment, 2021 – 2031 (USD Million)
TABLE 42 Rest of Asia-Pacific Acute Intermittent Porphyria Market Revenue, By End-users, 2021 – 2031 (USD Million)
TABLE 43 Middle East and Africa Acute Intermittent Porphyria Market Revenue, By Country, 2021 – 2031 (USD Million)
TABLE 44 Middle East and Africa Acute Intermittent Porphyria Market Revenue, By Treatment, 2021 – 2031 (USD Million)
TABLE 45 Middle East and Africa Acute Intermittent Porphyria Market Revenue, By End-users, 2021 – 2031 (USD Million)
TABLE 46 GCC Acute Intermittent Porphyria Market Revenue, By Treatment, 2021 – 2031 (USD Million)
TABLE 47 GCC Acute Intermittent Porphyria Market Revenue, By End-users, 2021 – 2031 (USD Million)
TABLE 48 North Africa Acute Intermittent Porphyria Market Revenue, By Treatment, 2021 – 2031 (USD Million)
TABLE 49 North Africa Acute Intermittent Porphyria Market Revenue, By End-users, 2021 – 2031 (USD Million)
TABLE 50 South Africa Acute Intermittent Porphyria Market Revenue, By Treatment, 2021 – 2031 (USD Million)
TABLE 51 South Africa Acute Intermittent Porphyria Market Revenue, By End-users, 2021 – 2031 (USD Million)
TABLE 52 Rest of Middle East & Africa Acute Intermittent Porphyria Market Revenue, By Treatment, 2021 – 2031 (USD Million)
TABLE 53 Rest of Middle East & Africa Acute Intermittent Porphyria Market Revenue, By End-users, 2021 – 2031 (USD Million)
TABLE 54 Latin America Acute Intermittent Porphyria Market Revenue, By Country, 2021 – 2031 (USD Million)
TABLE 55 Latin America Acute Intermittent Porphyria Market Revenue, By Treatment, 2021 – 2031 (USD Million)
TABLE 56 Latin America Acute Intermittent Porphyria Market Revenue, By End-users, 2021 – 2031 (USD Million)
TABLE 57 Brazil Acute Intermittent Porphyria Market Revenue, By Treatment, 2021 – 2031 (USD Million)
TABLE 58 Brazil Acute Intermittent Porphyria Market Revenue, By End-users, 2021 – 2031 (USD Million)
TABLE 59 Argentina Acute Intermittent Porphyria Market Revenue, By Treatment, 2021 – 2031 (USD Million)
TABLE 60 Argentina Acute Intermittent Porphyria Market Revenue, By End-users, 2021 – 2031 (USD Million)
TABLE 61 Rest of Latin America Acute Intermittent Porphyria Market Revenue, By Treatment, 2021 – 2031 (USD Million)
TABLE 62 Rest of Latin America Acute Intermittent Porphyria Market Revenue, By End-users, 2021 – 2031 (USD Million)
TABLE 63 Company Market Ranking
TABLE 64 Regional Footprint
TABLE 65 Product Benchmarking
TABLE 66 Recent Developments
TABLE 67 Winning Imperatives 

List of figures

FIG. 1 Market Segmentation
FIG. 2 Research Timeline
FIG. 3 Global Acute Intermittent Porphyria Market 2021-2031 (USD Million)
FIG. 4 Global Acute Intermittent Porphyria Market Geographical Analysis (CAGR %)
FIG. 5 Global Acute Intermittent Porphyria Absolute Market Opportunity (USD Million)
FIG. 6 Global Acute Intermittent Porphyria Market Attractiveness (USD Million)
FIG. 7 Global Acute Intermittent Porphyria Market, By Treatment, 2021-2031 (USD Million)
FIG. 8 Global Acute Intermittent Porphyria Market, By End-User, 2021-2031 (USD Million)
FIG. 9 Research Methodology
FIG. 10 Research Process
FIG. 11 Bottom-Up Approach
FIG. 12 Top-Bottom Approach
FIG. 13 Market Dynamics Overview
FIG. 14 Porter's Five Forces Analysis
FIG. 15 Value Chain Analysis
FIG. 16 Macroeconomic Analysis
FIG. 17 Global Acute Intermittent Porphyria Market Revenue Share, By Treatment, 2023 and 2031 (%)
FIG. 18 Global Acute Intermittent Porphyria Market Revenue Share, By End-User, 2023 and 2031 (%)
FIG. 19 Global Acute Intermittent Porphyria Market Revenue Share, By Geographic Regions, 2023 and 2031 (%)
FIG. 20 Market Size and Projections, 2021 - 2031 (USD Million)
FIG. 21 North America Acute Intermittent Porphyria Market Overview Share, By Countries, 2021 – 2031 (%)
FIG. 22 Market Size and Projections, 2021 - 2031 (USD Million)
FIG. 23 Europe Acute Intermittent Porphyria Market Overview Share, By Countries, 2021 – 2031 (%)
FIG. 24 Market Size and Projections, 2021 - 2031 (USD Million)
FIG. 25 Asia-Pacific Acute Intermittent Porphyria Market Overview Share, By Countries, 2021 – 2031 (%)
FIG. 26 Market Size and Projections, 2021 - 2031 (USD Million)
FIG. 27 Middle East & Africa Acute Intermittent Porphyria Market Overview Share, By Countries, 2021 – 2031 (%)
FIG. 28 Market Size and Projections, 2021 - 2031 (USD Million)
FIG. 29 Latin America Acute Intermittent Porphyria Market Overview Share, By Countries, 2021 – 2031 (%)
FIG. 30 Key Strategic Development
FIG. 31 Key Facts
FIG. 32 Financial Overview
FIG. 33 SWOT Analysis